Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial)
Authors:
- Yoshiaki NagataniYNYoshiaki Nagatani
- Naoko ChayaharaNCNaoko Chayahara
- Hironaga SatakeHSHironaga Satake
- Hisateru YasuiHYHisateru Yasui
- Takeshi SugimotoTakeshi Sugimoto
- Hirochika ToyamaHTHirochika Toyama
- Kazutoshi TobimatsuKTKazutoshi Tobimatsu
- Eriko ItoEIEriko Ito
- Yutaro UsuiYUYutaro Usui
- Taiji KoyamaTKTaiji Koyama
- Shiro KimbaraSKShiro Kimbara
- Yoshinori ImamuraYIYoshinori Imamura
- 10 September 2026
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 247
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trialThe Lancet, 2023
- Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized studyJournal of Cancer Research and Clinical Oncology, 2020
- Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial)Cancer Chemotherapy and Pharmacology, 2020
- Pancreatic cancerThe Lancet, 2020
- Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancerEuropean Journal of Cancer, 2016
- Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic CancerJAMA Surgery, 2016
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)The Lancet, 2016
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysisThe Lancet Oncology, 2016
- Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancerCancer Chemotherapy and Pharmacology, 2013